{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:23:16Z","timestamp":1786551796147,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,12]]},"DOI":"10.7759\/cureus.96713","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:14:36Z","timestamp":1763003676000},"source":"Crossref","is-referenced-by-count":2,"title":["The Obesity Drug Revolution: New Frontiers in Pharmacotherapy"],"prefix":"10.7759","author":[{"given":"Prabhash C","family":"Manoria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Obesity (Nursing)","author":"Panuganti KK","year":"2025","unstructured":"Panuganti KK, Nguyen M, Kshirsagar RK. Obesity (Nursing). StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL):; 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino F","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al.. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025, 13:221-62. 10.1016\/S2213-8587(24)00316-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","unstructured":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050. a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025, 405:813-38. 10.1016\/S0140-6736(25)00355-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2024.102882","article-title":"The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: a meta-analysis","volume":"46","author":"Islam AN","year":"2024","unstructured":"Islam AN, Sultana H, Nazmul Hassan Refat M, Farhana Z, Abdulbasah Kamil A, Meshbahur Rahman M. The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: a meta-analysis. Prev Med Rep. 2024, 46:102882. 10.1016\/j.pmedr.2024.102882","journal-title":"Prev Med Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009773","article-title":"Economic impacts of overweight and obesity: current and future estimates for 161 countries","volume":"7","author":"Okunogbe A","year":"2022","unstructured":"Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022, 7:e009773. 10.1136\/bmjgh-2022-009773","journal-title":"BMJ Glob Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2018.04.005","article-title":"Fighting obesity: non-pharmacological interventions","volume":"25","author":"Higuera-Hern\u00e1ndez MF","year":"2018","unstructured":"Higuera-Hern\u00e1ndez MF, Reyes-Cuapio E, Guti\u00e9rrez-Mendoza M, et al.. Fighting obesity: non-pharmacological interventions. Clin Nutr ESPEN. 2018, 25:50-5. 10.1016\/j.clnesp.2018.04.005","journal-title":"Clin Nutr ESPEN"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","author":"ElSayed NA","year":"2024","unstructured":"ElSayed NA, Aleppo G, Bannuru RR, et al.. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024, 47:S158-78. 10.2337\/dc24-S009","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7570\/jomes23016","article-title":"Evaluation and treatment of obesity and its comorbidities: 2022 update of clinical practice guidelines for obesity by the Korean Society for the study of obesity","volume":"32","author":"Kim KK","year":"2023","unstructured":"Kim KK, Haam JH, Kim BT, et al.. Evaluation and treatment of obesity and its comorbidities: 2022 update of clinical practice guidelines for obesity by the Korean Society for the study of obesity. J Obes Metab Syndr. 2023, 32:1-24. 10.7570\/jomes23016","journal-title":"J Obes Metab Syndr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1037\/amp0000517","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden TA","year":"2020","unstructured":"Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020, 75:235-51. 10.1037\/amp0000517","journal-title":"Am Psychol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly HM","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997, 337:581-8. 10.1056\/NEJM199708283370901","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1517\/14740330902931524","article-title":"Serotonergic drugs and valvular heart disease","volume":"8","author":"Rothman RB","year":"2009","unstructured":"Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf. 2009, 8:317-29. 10.1517\/14740330902931524","journal-title":"Expert Opin Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group","volume":"335","author":"Abenhaim L","year":"1996","unstructured":"Abenhaim L, Moride Y, Brenot F, et al.. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996, 335:609-16. 10.1056\/NEJM199608293350901","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James WP","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, et al.. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010, 363:905-17. 10.1056\/NEJMoa1003114","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/sui086","article-title":"The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients","volume":"7","author":"James WT","year":"2005","unstructured":"James WT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. EHJ-S. 2005, 7:44-8. 10.1093\/eurheartj\/sui086","journal-title":"EHJ-S"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn076","article-title":"Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study","volume":"29","author":"Van Gaal LF","year":"2008","unstructured":"Van Gaal LF, Scheen AJ, Rissanen AM, R\u00f6ssner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J. 2008, 29:1761-71. 10.1093\/eurheartj\/ehn076","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen SE","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, et al.. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008, 299:1547-60. 10.1001\/jama.299.13.1547","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen R","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007, 370:1706-13. 10.1016\/S0140-6736(07)61721-8","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0735-y","article-title":"Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review","volume":"14","author":"Onakpoya IJ","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016, 14:191. 10.1186\/s12916-016-0735-y","journal-title":"BMC Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sj\u00f6str\u00f6m L","year":"1998","unstructured":"Sj\u00f6str\u00f6m L, Rissanen A, Andersen T, et al.. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998, 352:167-72. 10.1016\/s0140-6736(97)11509-4","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/69.6.1108","article-title":"Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study","volume":"69","author":"Hill JO","year":"1999","unstructured":"Hill JO, Hauptman J, Anderson JW, et al.. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999, 69:1108-16. 10.1093\/ajcn\/69.6.1108","journal-title":"Am J Clin Nutr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.81938","article-title":"Evaluation of efficacy and safety of orlistat in obese patients","volume":"15","author":"Jain SS","year":"2011","unstructured":"Jain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab. 2011, 15:99-104. 10.4103\/2230-8210.81938","journal-title":"Indian J Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial","volume":"25","author":"Kelley DE","year":"2002","unstructured":"Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2002, 25:1033-41. 10.2337\/diacare.25.6.1033","journal-title":"Diabetes Care"},{"key":"ref23","unstructured":"Orlistat FDA Drug Label. Accessed. August 1, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020766s026lbl.pdf."},{"key":"ref24","unstructured":"Setmelanotide FDA Drug Label. Accessed. August 1, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213793s001lbl.pdf."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00273-0","article-title":"Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial","volume":"13","author":"Argente J","year":"2025","unstructured":"Argente J, Verge CF, Okorie U, et al.. Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2025, 13:29-37. 10.1016\/S2213-8587(24)00273-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00277-7","article-title":"Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period","volume":"10","author":"Haqq AM","year":"2022","unstructured":"Haqq AM, Chung WK, Dollfus H, et al.. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022, 10:859-68. 10.1016\/S2213-8587(22)00277-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref27","unstructured":"Phentermine and Topiramate FDC FDA Drug Label\r\n . Accessed. August 2, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022580s025lbl.pdf."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde KM","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, et al.. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011, 377:1341-52. 10.1016\/S0140-6736(11)60205-5","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey WT","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, et al.. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012, 95:297-308. 10.3945\/ajcn.111.024927","journal-title":"Am J Clin Nutr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison DB","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, et al.. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012, 20:330-42. 10.1038\/oby.2011.330","journal-title":"Obesity (Silver Spring)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100099","article-title":"Effects of phentermine \/ topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: a randomized, multicenter, double-blind study","volume":"9","author":"Bays HE","year":"2024","unstructured":"Bays HE, Hsia DS, Nguyen LT, Peterson CA, Varghese ST. Effects of phentermine \/ topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: a randomized, multicenter, double-blind study. Obes Pillars. 2024, 9:100099. 10.1016\/j.obpill.2024.100099","journal-title":"Obes Pillars"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly AS","year":"2022","unstructured":"Kelly AS, Bensignor MO, Hsia DS, Shoemaker AH, Shih W, Peterson C, Varghese ST. Phentermine\/topiramate for the treatment of adolescent obesity. NEJM Evid. 2022, 1:10.1056\/evidoa2200014","journal-title":"NEJM Evid"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne LJ","year":"2013","unstructured":"Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013, 21:2163-71. 10.1002\/oby.20584","journal-title":"Obesity (Silver Spring)"},{"key":"ref34","unstructured":"Naltrexone and Bupropion FDC Combination FDA Drug Label. Accessed. August 2, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/200063s020lbl.pdf."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway FL","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, et al.. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010, 376:595-605. 10.1016\/S0140-6736(10)60888-4","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian CM","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, et al.. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013, 21:935-43. 10.1002\/oby.20309","journal-title":"Obesity (Silver Spring)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden TA","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, et al.. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011, 19:110-20. 10.1038\/oby.2010.147","journal-title":"Obesity (Silver Spring)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.10.010","article-title":"Naltrexone + bupropion combination for the treatment of binge-eating disorder with obesity: a randomized, controlled pilot study","volume":"43","author":"Grilo CM","year":"2021","unstructured":"Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + bupropion combination for the treatment of binge-eating disorder with obesity: a randomized, controlled pilot study. Clin Ther. 2021, 43:112-122.e1. 10.1016\/j.clinthera.2020.10.010","journal-title":"Clin Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01319-7","article-title":"The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials","volume":"16","author":"Liu Y","year":"2024","unstructured":"Liu Y, Han F, Xia Z, Sun P, Rohani P, Amirthalingam P, Sohouli MH. The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials. Diabetol Metab Syndr. 2024, 16:93. 10.1186\/s13098-024-01319-7","journal-title":"Diabetol Metab Syndr"},{"key":"ref40","unstructured":"Liraglutide FDA Drug Label. Accessed. August 2, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022341s027lbl.pdf."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer X","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al.. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015, 373:11-22. 10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly AS","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, et al.. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020, 382:2117-28. 10.1056\/NEJMoa1916038","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23481","article-title":"Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial","volume":"30","author":"Maselli D","year":"2022","unstructured":"Maselli D, Atieh J, Clark MM, et al.. Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial. Obesity (Silver Spring). 2022, 30:1608-20. 10.1002\/oby.23481","journal-title":"Obesity (Silver Spring)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11112998","article-title":"Efficacy of liraglutide in non-diabetic obese adults: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Barboza JJ","year":"2022","unstructured":"Barboza JJ, Huam\u00e1n MR, Melgar B, Diaz-Arocutipa C, Valenzuela-Rodriguez G, Hernandez AV. Efficacy of liraglutide in non-diabetic obese adults: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2022, 11:2998. 10.3390\/jcm11112998","journal-title":"J Clin Med"},{"key":"ref45","unstructured":"Semaglutide FDA Drug Label. Accessed. August 3, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies M","year":"2021","unstructured":"Davies M, Faerch L, Jeppesen OK, et al.. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021, 397:971-84. 10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al.. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024, 390:1394-407. 10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref51","unstructured":"Tirzepatide FDA Drug Label. Accessed. August 3, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217806s013lbl.pdf."},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT- 2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey WT","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT- 2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023, 402:613-26. 10.1016\/S0140-6736(23)01200-X","journal-title":"Lancet"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden TA","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al.. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023, 29:2909-18. 10.1038\/s41591-023-02597-w","journal-title":"Nat Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10816","article-title":"Medications for obesity: a review","volume":"332","author":"Gudzune KA","year":"2024","unstructured":"Gudzune KA, Kushner RF. Medications for obesity: a review. JAMA. 2024, 332:571-84. 10.1001\/jama.2024.10816","journal-title":"JAMA"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101100","article-title":"Recent achievements and future directions of anti-obesity medications","volume":"47","author":"Grandl G","year":"2024","unstructured":"Grandl G, Novikoff A, Liu X, M\u00fcller TD. Recent achievements and future directions of anti-obesity medications. Lancet Reg Health Eur. 2024, 47:101100. 10.1016\/j.lanepe.2024.101100","journal-title":"Lancet Reg Health Eur"},{"key":"ref58","unstructured":"Lilly\u2019s Oral GLP-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent With Injectable GLP-1 Medicines in Successful Phase 3 Trial. Accessed. August 3, 2025: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-oral-glp-1-orforglipron-demonstrated-statistically."},{"key":"ref59","doi-asserted-by":"crossref","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson E","year":"2025","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity?. Int J Obes. 2025, 49:433-51.","journal-title":"Int J Obes"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01561-z","article-title":"Understanding the complex function of gut microbiota: its impact on the pathogenesis of obesity and beyond: a comprehensive review","volume":"16","author":"Yarahmadi A","year":"2024","unstructured":"Yarahmadi A, Afkhami H, Javadi A, Kashfi M. Understanding the complex function of gut microbiota: its impact on the pathogenesis of obesity and beyond: a comprehensive review. Diabetol Metab Syndr. 2024, 16:308. 10.1186\/s13098-024-01561-z","journal-title":"Diabetol Metab Syndr"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3746\/pnf.2020.25.2.113","article-title":"The influence of the gut microbiome on obesity in adults and the role of probiotics, prebiotics, and synbiotics for weight loss","volume":"25","author":"Aoun A","year":"2020","unstructured":"Aoun A, Darwish F, Hamod N. The influence of the gut microbiome on obesity in adults and the role of probiotics, prebiotics, and synbiotics for weight loss. Prev Nutr Food Sci. 2020, 25:113-23. 10.3746\/pnf.2020.25.2.113","journal-title":"Prev Nutr Food Sci"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16298-2","article-title":"Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice","volume":"11","author":"Alexopoulos SJ","year":"2020","unstructured":"Alexopoulos SJ, Chen SY, Brandon AE, et al.. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nat Commun. 2020, 11:2397. 10.1038\/s41467-020-16298-2","journal-title":"Nat Commun"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.2337\/dbi23-0033","article-title":"A new mitochondrial uncoupler improves metabolic homeostasis in mice","volume":"73","author":"Ramshankar G","year":"2024","unstructured":"Ramshankar G, Perry RJ. A new mitochondrial uncoupler improves metabolic homeostasis in mice. Diabetes. 2024, 73:357-8. 10.2337\/dbi23-0033","journal-title":"Diabetes"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.7570\/jomes20124","article-title":"Barriers to obesity management: patient and physician factors","volume":"29","author":"Kim TN","year":"2020","unstructured":"Kim TN. Barriers to obesity management: patient and physician factors. J Obes Metab Syndr. 2020, 29:244-7. 10.7570\/jomes20124","journal-title":"J Obes Metab Syndr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406748-the-obesity-drug-revolution-new-frontiers-in-pharmacotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:14:41Z","timestamp":1763003681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406748-the-obesity-drug-revolution-new-frontiers-in-pharmacotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":64,"URL":"https:\/\/doi.org\/10.7759\/cureus.96713","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}